Gabapentin occupies a curious place in the pharmacopeia. Originally developed as an analog of the neurotransmitter GABA, it does not actually act on GABA receptors at all. Instead, it binds to the α2δ-1 subunit of voltage-gated calcium channels, damping the excessive calcium influx into overexcited neurons that underlies neuropathic pain signaling. It remains a first-line therapy for conditions such as diabetic neuropathy, postherpetic neuralgia, and sciatica. Yet the drug carries well-known liabilities when taken orally: dizziness, somnolence, and fatigue are common, and its absorption from the gut is saturable and variable, meaning that higher doses do not translate proportionally into higher blood levels. Those limitations have long tempted formulation scientists to attempt a topical version — but gabapentin is a small, highly water-soluble, hydrophilic molecule, precisely the kind of compound that strug­gles to breach the skin’s lipid-rich outer barrier, the stratum corneum.

The Jamia Hamdard team, led by Parnika Vasudeva and Shama Parveen, who contributed equally as first authors, alongside colleagues including Ahsan Ali, Vijay Kumar, Pooja Jain, Mohd. Aamir Mirza, and senior author Zeenat Iqbal, attacked this permeability problem with nanostructured lipid carriers, or NLCs. These particles represent a second-generation evolution of solid lipid nanoparticles. Where their predecessors were built from a single solid lipid prone to crystallizing into an orderly lattice that expelled trapped drug molecules over time, NLCs blend a solid lipid with a liquid lipid in deliberate imbalance. The resulting imperfect, porous matrix has room for drug molecules to hide, boosting how much drug each particle can carry and preventing the payload from leaking out during storage.

To build their carriers, the researchers turned to a systematic engineering philosophy known as quality by design, or QbD — an approach borrowed from manufacturing science in which formulation variables are treated as inputs to be rationally optimized rather than trial-and-error guesses. The team varied critical parameters and measured four key quality attributes of the resulting nanoparticles: particle size, zeta potential, drug entrapment efficiency, and in vitro drug release. Each of these numbers matters. Particle size governs how densely the carriers can pack onto the skin surface and how readily they slip into hair follicles and microscopic skin furrows. Zeta potential — the electrical charge at the particle surface — predicts whether particles will repel one another and remain stably dispersed or clump into useless aggregates. Entrapment efficiency reveals what fraction of the expensive drug payload actually ended up inside the carriers rather than floating free in the watery surroundings.

The optimization paid off. The winning formulation produced particles averaging just 144.4 nanometers in diameter — small enough that roughly 700 particles lined up side by side would span the width of a human hair. The system was moderately polydisperse, with a polydispersity index of 0.331, indicating a reasonably uniform population of carriers. The zeta potential measured −27.2 millivolts, a strongly negative surface charge comfortably within the range generally considered sufficient to keep nanoparticles from aggregating through electrostatic repulsion. Perhaps most importantly, the carriers succeeded at the very task that makes topical gabapentin so difficult: by tucking the hydrophilic drug inside a lipid shell, they created a vehicle in which gabapentin can partition into, and diffuse across, the lipophilic stratum corneum far more effectively than the free drug ever could.

With the nanoparticles optimized, the next step was to convert them into something a patient could actually use. The researchers dispersed their NLC formulation into a gel matrix built from Carbopol 934, a synthetic polymer that swells in water to form a smooth, translucent, and highly stable gel. The finished 1 percent NLC gel was assessed against the practical criteria that determine whether a topical product will ever leave the laboratory: homogeneity, spreadability, pH, and extrudability — that is, how easily the gel can be squeezed from a tube. The formulation scored well across the board, exhibiting excellent homogeneity and spreadability, a skin-friendly pH, and smooth extrusion, all essential properties for a product intended for daily self-application on painful limbs.

The drug release behavior of the gel proved equally encouraging. In laboratory dissolution testing, 96.88 percent of the loaded gabapentin was released from the optimized NLC gel over six hours. When the researchers plotted the release data against mathematical kinetic models, the profile followed the Higuchi model — the classic signature of diffusion-controlled release from a matrix. In practical terms, this means the drug does not burst out all at once but instead diffuses steadily out of the lipid matrix at a rate governed by the square root of time, exactly the sustained, gradual delivery profile desired for a pain therapy that must keep working between applications.

The true test, however, had to come from living nerves. The team turned to a widely used animal model of neuropathic pain known as chronic constriction injury, or CCI. In this model, Wistar rats undergo surgical loosening of the sciatic nerve, producing partial denervation that mirrors the mechanical nerve damage seen in human conditions such as sciatica and complex regional pain syndrome. Within days, the injured nerve generates the hallmark abnormalities of neuropathic pain: heightened sensitivity to heat and touch, known as hyperalgesia, and pain responses to normally innocuous stimuli, known as allodynia.

Rats with CCI-induced nerve injury were treated with the gabapentin-loaded NLC gel, and their pain responses were evaluated using two established behavioral assays of thermal sensitivity: the tail-immersion test, which measures how quickly an animal withdraws its tail from warm water, and the hot plate test, which measures latency to respond when placed on a heated surface. The treated animals showed promising improvements in heat sensitivity across both tests, indicating that the drug delivered through the skin was reaching functional targets and dampening the aberrant nerve signaling produced by the injury. The result demonstrates that enough gabapentin penetrated the rat skin to exert a pharmacodynamic effect at the peripheral nerves — the central hurdle that has defeated simpler topical gabapentin attempts in the past.

The implications extend beyond one drug and one disease. Peripheral neuropathic pain affects a substantial fraction of people with diabetes, and it complicates cancer chemotherapy, shingles infection, spinal surgery, and traumatic nerve injury. Current consensus guidelines place gabapentin and its cousin pregabalin at the top of the pharmacological ladder, but their systemic side effects force many patients to abandon treatment. A topical alternative that concentrates drug delivery at the painful site while minimizing blood levels could transform daily management, offering relief with a fraction of the dizziness and drowsiness that undermine oral therapy. The lipid nanoparticles themselves may also provide synergistic benefits: lipid-based carriers are known to interact with and disrupt the stratum corneum’s lipid architecture transiently, opening transient channels for penetration, and their occlusive film-forming behavior on the skin can further enhance hydration and permeability.

The authors conclude that a gabapentin-containing NLC gel can be a better alternative to oral formulations and merits further exploration for peripheral neuropathic pain. There is still a considerable distance between a rat model and a pharmacy shelf. The findings will need confirmation in larger animal studies, formal skin toxicity and irritation testing, pharmacokinetic measurements of how much drug reaches the bloodstream versus the target tissue, and ultimately carefully controlled clinical trials in human patients. Dose optimization, long-term stability of the gel, and scalability of the manufacturing process will all demand attention. But the study offers a compelling proof of concept: that quality-by-design engineering of nanostructured lipid carriers can coax a stubbornly hydrophilic drug through the body’s most formidable barrier and quiet damaged nerves where they misfire. For the millions who live with burning feet and shooting limb pain, the prospect of relief from a simple tube of gel — without the fog of systemic side effects — is a future worth watching closely.

The research team focused on elucidating how epigenetic modifications influence gene expression within sensory neurons that are critical to the initiation and maintenance of neuropathic pain. Epigenetics, comprising DNA methylation, histone modifications, and chromatin remodeling, plays a significant role in turning genes on or off without altering the underlying DNA sequence. ZFP612, a zinc finger protein previously uncharacterized in this context, was identified as a major player orchestrating the repression of Il1rl1, a gene encoding a receptor implicated in inflammatory pain signaling.

By employing male mice models subjected to neuropathic injury, Ma and colleagues meticulously dissected the neural mechanisms that underlie persistent pain states. Their experimental design combined behavioral pain assessments with advanced molecular techniques such as chromatin immunoprecipitation followed by sequencing (ChIP-seq). These methods revealed that ZFP612 binds to specific silencer regions creating a closed-loop between the gene’s promoter and silencer elements, effectively preventing transcriptional activation of Il1rl1.

The significance of the silencer–promoter loop lies in its ability to maintain the gene in a transcriptionally repressed state. This three-dimensional chromatin structure imposes tight control over Il1rl1 expression, ensuring that the receptor’s inflammatory pathways remain subdued under normal conditions. However, in neuropathic pain states, disruptions in this loop may lead to aberrant gene activation, exacerbating inflammatory signaling and sustained pain sensitivity.

Importantly, the study delineates that ZFP612’s regulatory function is specific to male mice, suggesting sex-specific epigenetic regulatory mechanisms in pain processing. This observation calls for a nuanced understanding of how sex differences contribute to the prevalence and persistence of neuropathic pain and may explain why some treatments show differential efficacy between males and females.

The molecular insights provided by this study extend beyond mere gene expression modulation; they highlight the role of complex chromatin architecture in sensory neuron function. By repressing Il1rl1 through an epigenetic silencer–promoter loop, ZFP612 acts as a molecular gatekeeper, limiting excessive inflammatory signaling that would otherwise heighten pain perception. This discovery underscores the multifaceted nature of pain epigenetics, encompassing not only individual gene regulation but also the spatial organization of chromatin.

Therapeutic targeting of ZFP612 or the associated silencer–promoter loop structures could revolutionize approaches to neuropathic pain management. Current analgesics are often limited by efficacy and side effects, while gene therapy or small molecules designed to modulate epigenetic regulators offer promise for more precise intervention. The identification of ZFP612 as a key repressor opens the door to drug development efforts aimed at restoring proper epigenetic control in pain-related genes.

Moreover, this research highlights the importance of studying chromatin topology and its functional repercussions in disease states. The three-dimensional arrangement of chromatin constituting silencer-promoter loops is increasingly recognized as an essential layer of gene regulation. The integration of epigenomic profiling with functional assessments in neuronal circuits, as performed by Ma et al., exemplifies the power of multidisciplinary research in unraveling complex disease mechanisms.

This work also emphasizes the role of primary sensory neurons as not just passive conduits for pain signals but as dynamic centers of gene regulation that adapt epigenetically to injury. Understanding how neurons engage epigenetic machinery to regulate gene expression in response to pathological stimuli is crucial for developing therapies that block the transition from acute to chronic pain states.

ZFP612’s selective repression of Il1rl1 in primary sensory neurons reveals new biology in the inflammatory pathways contributing to neuropathic pain. Il1rl1, also known as the interleukin-33 receptor (ST2), activates downstream cascades leading to inflammatory mediator release and nociceptor sensitization. Controlling this receptor’s expression epigenetically may thus calibrate the neuronal inflammatory response and reduce pain hypersensitivity.

The sex-specific findings underscore the need for personalized pain medicine approaches that take into account biological variability between males and females. Epigenetic regulators like ZFP612 may exhibit differential expression or activity across sexes, shaping distinct epigenomic landscapes and therapeutic susceptibilities. Future studies will be essential to explore these dimensions and translate findings toward clinical application.

Collectively, the notion of epigenetic repression via chromatin looping expands our paradigm for gene regulation in pain pathophysiology. It moves beyond classical promoter or enhancer-centric views to incorporate higher-order chromatin interactions as critical determinants of gene expression states. ZFP612 exemplifies how transcriptional silencers cooperate with promoters through physical interactions driven by epigenetic readers and writers to maintain neuronal homeostasis.

The implications extend to other neurological disorders where epigenetic dysregulation and aberrant gene expression contribute to disease progression. Insights gained from the neuropathic pain model may inform broader strategies for modulating epigenetic architectures in the nervous system to restore normal function.

Ultimately, this pioneering research by Ma and colleagues provides a compelling framework for novel pain interventions grounded in molecular epigenetics. By unveiling ZFP612 as a master regulator modulating pain-relevant gene expression through chromatin looping, it sets the stage for transformational advances in understanding and treating neuropathic pain. Further exploration of these pathways holds promise for alleviating suffering and improving quality of life for those afflicted by chronic pain.

Subject of Research: Epigenetic regulation of neuropathic pain mechanisms in primary sensory neurons of male mice

Article Title: ZFP612 controls neuropathic pain through epigenetic repression of Il1rl1 within the silencer–promoter loop in primary sensory neurons of male mice

Article References:
Ma, L., Huang, Y., Han, M. et al. ZFP612 controls neuropathic pain through epigenetic repression of Il1rl1 within the silencer–promoter loop in primary sensory neurons of male mice. Nat Commun 16, 10701 (2025). https://doi.org/10.1038/s41467-025-65935-1

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-65935-1